4Q Revenues: $1.8 billion (+5%)
4Q Earnings: $95 million (earnings were $763 million 4Q14)
FY Revenues: $6.1 billion (+3%)
FY Earnings: $956 million (-47%)
Comments: Hematology revenues were $1.0 billion in the quarter, down 2%. Immunology revenues were $680 million, up 8%. Oncology revenues were $53 million from the acquisition of ONCASPAR (pegaspargase) leukemia portfolio from Sigma-Tau. Results include after-tax special items totaling $292 million, primarily for asset repayment, expenses associated with the company’s separation from Baxter International, and certain business development and collaboration-related items.